D. E. Shaw & Co. Inc. Purchases 48,270 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

D. E. Shaw & Co. Inc. increased its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 23.3% during the second quarter, Holdings Channel.com reports. The firm owned 255,871 shares of the specialty pharmaceutical company’s stock after buying an additional 48,270 shares during the quarter. D. E. Shaw & Co. Inc.’s holdings in Jazz Pharmaceuticals were worth $27,309,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Jazz Pharmaceuticals in the 2nd quarter worth $1,064,000. Distillate Capital Partners LLC bought a new stake in Jazz Pharmaceuticals in the 2nd quarter worth about $14,026,000. Point72 DIFC Ltd purchased a new stake in Jazz Pharmaceuticals in the 2nd quarter valued at about $1,823,000. EverSource Wealth Advisors LLC lifted its position in shares of Jazz Pharmaceuticals by 55.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock worth $30,000 after buying an additional 97 shares in the last quarter. Finally, Itau Unibanco Holding S.A. purchased a new position in shares of Jazz Pharmaceuticals in the 2nd quarter worth approximately $29,000. 89.14% of the stock is currently owned by institutional investors.

Jazz Pharmaceuticals Stock Up 0.7 %

Jazz Pharmaceuticals stock opened at $110.93 on Friday. Jazz Pharmaceuticals plc has a 1-year low of $99.06 and a 1-year high of $137.38. The firm has a market capitalization of $7.00 billion, a price-to-earnings ratio of 22.87, a P/E/G ratio of 1.36 and a beta of 0.57. The company has a current ratio of 2.37, a quick ratio of 2.02 and a debt-to-equity ratio of 1.36. The firm has a 50 day simple moving average of $111.02 and a 200 day simple moving average of $110.82.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings data on Wednesday, July 31st. The specialty pharmaceutical company reported $4.67 earnings per share for the quarter, beating analysts’ consensus estimates of $3.80 by $0.87. Jazz Pharmaceuticals had a net margin of 10.10% and a return on equity of 28.65%. The business had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1 billion. On average, analysts predict that Jazz Pharmaceuticals plc will post 16.03 earnings per share for the current year.

Insider Buying and Selling at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, SVP Mary Elizabeth Henderson sold 1,410 shares of the firm’s stock in a transaction on Friday, September 6th. The shares were sold at an average price of $108.30, for a total value of $152,703.00. Following the completion of the transaction, the senior vice president now directly owns 14,531 shares of the company’s stock, valued at approximately $1,573,707.30. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 4.20% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Morgan Stanley dropped their price target on Jazz Pharmaceuticals from $160.00 to $150.00 and set an “equal weight” rating on the stock in a report on Friday, July 12th. Wells Fargo & Company dropped their target price on shares of Jazz Pharmaceuticals from $140.00 to $120.00 and set an “equal weight” rating on the stock in a research note on Thursday, August 1st. HC Wainwright restated a “buy” rating and set a $200.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday, August 1st. The Goldman Sachs Group assumed coverage on shares of Jazz Pharmaceuticals in a research note on Wednesday, June 5th. They set a “buy” rating and a $169.00 price target for the company. Finally, Piper Sandler decreased their price target on shares of Jazz Pharmaceuticals from $188.00 to $166.00 and set an “overweight” rating for the company in a research note on Thursday, August 1st. Three research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $173.07.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.